Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure.

[1]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[2]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[3]  P. Kirchhof,et al.  Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis , 2016, British Medical Journal.

[4]  J. Cleland,et al.  Should β-blockers be used in patients with heart failure and atrial fibrillation? , 2015, Clinical therapeutics.

[5]  J. Piccini,et al.  Controversies in cardiovascular medicine Atrial fibrillation in heart failure : what should we do ? , 2015 .

[6]  G. Fonarow,et al.  Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) , 2015, Journal of the American Heart Association.

[7]  L. Lund,et al.  Prognostic Significance of Resting Heart Rate and Use of &bgr;-Blockers in Atrial Fibrillation and Sinus Rhythm in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Swedish Heart Failure Registry , 2015, Circulation. Heart failure.

[8]  Piotr Ponikowski,et al.  The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. , 2015, European heart journal.

[9]  Richard D Riley,et al.  Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data: The PRISMA-IPD Statement , 2015 .

[10]  S. Solomon,et al.  Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. , 2015, European heart journal.

[11]  P. Kirchhof,et al.  Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis , 2014, The Lancet.

[12]  F. Edelmann,et al.  Heart rate following short‐term beta‐blocker titration predicts all‐cause mortality in elderly chronic heart failure patients: insights from the CIBIS‐ELD trial , 2014, European journal of heart failure.

[13]  R. McKelvie,et al.  Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I‐Preserve) , 2014, European journal of heart failure.

[14]  John G F Cleland,et al.  Is heart rate important for patients with heart failure in atrial fibrillation? , 2014, JACC. Heart failure.

[15]  R. Nagai,et al.  Differential impacts of achieved heart rate and achieved dose of β-blocker on clinical outcomes in heart failure with and without atrial fibrillation. , 2014, International Journal of Cardiology.

[16]  H. Crijns,et al.  Lenient vs. strict rate control in patients with atrial fibrillation and heart failure: a post‐hoc analysis of the RACE II study , 2013, European journal of heart failure.

[17]  D. Altman,et al.  Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design , 2013, Systematic Reviews.

[18]  J. Cleland,et al.  Heart rate achieved or beta‐blocker dose in patients with chronic heart failure: which is the better target? , 2012, European journal of heart failure.

[19]  Michael Böhm,et al.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2010, The Lancet.

[20]  N. Freemantle,et al.  Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR‐HF, J‐CHF, HeartMate II, PACE and a meta‐analysis of dose‐ranging studies of beta‐blockers in heart failure , 2010, European journal of heart failure.

[21]  Natasha Wiebe,et al.  Meta-analysis: -Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure , 2009, Annals of Internal Medicine.

[22]  A. Hoes,et al.  Empirical comparison of subgroup effects in conventional and individual patient data meta-analyses , 2008, International Journal of Technology Assessment in Health Care.

[23]  P. Williamson,et al.  A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes , 2007, Clinical trials.

[24]  P. Poole‐Wilson,et al.  Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. , 2007, American heart journal.

[25]  D. J. Veldhuisen,et al.  Presence and development of atrial fibrillation in chronic heart failure , 2006, European journal of heart failure.

[26]  Paula R Williamson,et al.  Investigating heterogeneity in an individual patient data meta‐analysis of time to event outcomes , 2005, Statistics in medicine.

[27]  A. Cohen-Solal,et al.  Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). , 2005, European heart journal.

[28]  S. Gottlieb,et al.  What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF). , 2005, Journal of the American College of Cardiology.

[29]  P. Royston,et al.  A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials , 2004, Statistics in medicine.

[30]  M. Pfeffer,et al.  Adverse mortality effect of central sympathetic inhibition with sustained‐release moxonidine in patients with heart failure (MOXCON) , 2003, European journal of heart failure.

[31]  P. Macfarlane,et al.  Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial , 2003, The Lancet.

[32]  B. Fagerberg,et al.  Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). , 2002, Journal of the American College of Cardiology.

[33]  D. DeMets,et al.  Effect of carvedilol on survival in severe chronic heart failure. , 2001, The New England journal of medicine.

[34]  M. Domanski,et al.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. , 2001, The New England journal of medicine.

[35]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[36]  James Rochon,et al.  Issues in Adjusting for Covariates Arising Postrandomization in Clinical Trials , 1999 .

[37]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[38]  CIBIS-II Investigators and Committees.  The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.

[39]  Australia..  Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease , 1997, The Lancet.

[40]  K. Adams,et al.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. , 1996, Circulation.

[41]  J. Cohn,et al.  The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.

[42]  L. Wilkins.  A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. , 1994, Circulation.

[43]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[44]  David A. Schoenfeld,et al.  Partial residuals for the proportional hazards regression model , 1982 .

[45]  A. Jacobson,et al.  Heart rate control in patients with chronic atrial fibrillation and heart failure. , 2013, Congestive heart failure.

[46]  A. Hjalmarson.  Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? , 2000, Basic Research in Cardiology.

[47]  P. Royston,et al.  Building multivariable prognostic and diagnostic models: transformation of the predictors by using fractional polynomials , 1999 .